German DRG (diagnosis related groups) system not yet out of the woods
This article was originally published in Clinica
Executive Summary
The German government's draft ordinance for the diagnosis related groups (DRG) system for hospital reimbursement has reached yet another stumbling block after this week's rejection by the federal association of statutory health insurance physicians (KBV). The KBV has added to misgivings expressed by the medical device industry association, BVMed (see Clinica No 1025, p 6), claiming that, in its current form, the DRG system would endanger outpatient care.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.